Alpha-MSH vs Met-Enkephalin

Melanocortin peptide; activates MC1R (pigmentation/anti-inflammatory), MC3R (energy balance), MC4R (appetite); suppresses NF-κB and pro-inflammatory cytokines

α-Melanocyte-stimulating hormone (α-MSH) is an endogenous 13-amino-acid peptide derived from proteolytic processing of proopiomelanocortin (POMC) that acts through melanocortin receptors (MC1R–MC5R), with biological roles including skin pigmentation, anti-inflammatory signaling, thermoregulation, and energy homeostasis. Its anti-inflammatory actions are mediated principally through MC1R and MC3R activation, leading to inhibition of NF-κB-dependent cytokine production, reduction of pro-inflammatory mediators including IL-1β and TNF-α, and modulation of leukocyte activity in both peripheral and central nervous system compartments. Research published in the Annals of the New York Academy of Sciences has characterized the mechanisms of α-MSH's anti-inflammatory activity in vivo and in vitro, and subsequent work has described new insights into its immunomodulatory functions and therapeutic potential in inflammatory conditions. α-MSH is a research compound with no FDA approval for any indication; no human clinical trials have established safety or efficacy for exogenous α-MSH administration in anti-inflammatory, neuroprotective, or other therapeutic contexts. Alpha-MSH and the melanocortin peptide family α-MSH is the prototype endogenous ligand for the melanocortin receptor family — five receptors (MC1R–MC5R) with distinct tissue distribution and functions. The pharmacological development of synthetic melanocortin analogues has produced several clinically and commercially relevant compounds derived from or inspired by α-MSH: Melanotan I (afamelanotide, MC1R-selective, approved as Scenesse for erythropoietic protoporphyria), Melanotan II (non-selective, superpotent, never approved; extensively used in research), and PT-141/bremelanotide (cyclized Melanotan II analogue, FDA-approved as Vyleesi for female hypoactive sexual desire disorder via MC3R/MC4R). α-MSH itself serves as the structural reference point for this lineage — the pharmacophore binding sequence (His-Phe-Arg-Trp) shared by all active melanocortin analogues is derived from α-MSH residues 6–9. Appetite regulation and obesity research: α-MSH's role in energy homeostasis is mediated through MC4R activation in the hypothalamus, where it acts as an endogenous satiety signal opposing the appetitive effects of AgRP (agouti-related protein). Loss-of-function MC4R mutations are the most common monogenic cause of severe early-onset obesity, establishing the α-MSH/MC4R pathway as a validated target for pharmacological weight management. Setmelanotide (Imcivree), an MC4R agonist, is FDA-approved for obesity caused by MC4R pathway deficiency mutations (POMC deficiency, PCSK1 deficiency, leptin receptor deficiency) — a direct pharmacological descendant of the α-MSH mechanism.

Binds OGF receptors (zeta opioid receptors) on cell nuclei, regulating DNA synthesis and cell proliferation in a tonic inhibitory manner. Also binds delta opioid receptors. Intermittent blockade by low-dose naltrexone upregulates receptor expression and endogenous MENK tone.

Methionine enkephalin (Met-enkephalin; opioid growth factor, OGF) is an endogenous pentapeptide (Tyr-Gly-Gly-Phe-Met) that acts at classical mu- and delta-opioid receptors for pain modulation and, in its OGF role, functions as a tonic inhibitor of cell proliferation through interactions with the nuclear OGF receptor (OGFr, the zeta-opioid receptor), a pathway with distinct biological implications from classical analgesic opioid signaling. The OGF-OGFr axis operates as an endogenous homeostatic brake on cell cycle progression: OGF binds OGFr in the nucleus to upregulate cyclin-dependent kinase inhibitors p16 and p21, inhibiting S-phase entry; this mechanism has been characterized in models of wound repair, organ development, and immune cell regulation. Research from the Zagon laboratory has described the OGF-OGFr axis as a broad homeostatic regulator of cell proliferation and has established that the duration of opioid receptor blockade determines biotherapeutic response magnitude — the mechanistic basis for proposed low-dose naltrexone-mediated OGF upregulation in inflammatory and neoplastic conditions. Methionine enkephalin has no FDA-approved therapeutic applications as an exogenous agent; the OGF pathway has been characterized through preclinical and early-stage research, and exogenous OGF administration for any indication has not established a human clinical evidence base or received regulatory approval.